Cheng Luo

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/9031440/publications.pdf

Version: 2024-02-01

131 papers	4,716 citations	168829 31 h-index	139680 61 g-index
135 all docs	135 docs citations	135 times ranked	7284 citing authors

#	Article	IF	Citations
1	PRMT6 promotes tumorigenicity and cisplatin response of lung cancer through triggering 6PGD/ENO1 mediated cell metabolism. Acta Pharmaceutica Sinica B, 2023, 13, 157-173.	5.7	15
2	P300/CBP inhibition sensitizes mantle cell lymphoma to PI3KÎ´ inhibitor idelalisib. Acta Pharmacologica Sinica, 2022, 43, 457-469.	2.8	10
3	Natural product 1,2,3,4,6-penta-O-galloyl-Î²-D-glucopyranose is a reversible inhibitor of glyceraldehyde 3-phosphate dehydrogenase. Acta Pharmacologica Sinica, 2022, 43, 470-482.	2.8	9
4	High-Throughput-Methyl-Reading (HTMR) assay: a solution based on nucleotide methyl-binding proteins enables large-scale screening for DNA/RNA methyltransferases and demethylases. Nucleic Acids Research, 2022, 50, e9-e9.	6.5	12
5	Targeting the RT loop of Src SH3 in Platelets Prevents Thrombosis without Compromising Hemostasis. Advanced Science, 2022, 9, e2103228.	5.6	4
6	Spiroarborin, an ent-Clerodane Homodimer from Callicarpa arborea as an Inhibitor of the Eleven-Nineteen Leukemia (ENL) Protein by Targeting the YEATS Domain. Journal of Natural Products, 2022, 85, 317-326.	1.5	10
7	Identification, Synthesis, and Biological Evaluations of Potent Inhibitors Targeting Type I Protein Arginine Methyltransferases. Journal of Chemical Information and Modeling, 2022, 62, 692-702.	2.5	5
8	Computational and Structure-Based Development of High Potent Cell-Active Covalent Inhibitor Targeting the Peptidyl-Prolyl Isomerase NIMA-Interacting-1 (Pin1). Journal of Medicinal Chemistry, 2022, 65, 2174-2190.	2.9	11
9	The p300 Inhibitor A-485 Exerts Antitumor Activity in Growth Hormone Pituitary Adenoma. Journal of Clinical Endocrinology and Metabolism, 2022, 107, e2291-e2300.	1.8	15
10	Discovery of a highly potent CECR2 bromodomain inhibitor with 7H-pyrrolo[2,3-d] pyrimidine scaffold. Bioorganic Chemistry, 2022, 123, 105768.	2.0	3
11	A loosened gating mechanism of RIG-I leads to autoimmune disorders. Nucleic Acids Research, 2022, 50, 5850-5863.	6.5	9
12	Selective bromodomain and extra-terminal bromodomain inhibitor inactivates macrophages and hepatic stellate cells to inhibit liver inflammation and fibrosis. Bioengineered, 2022, 13, 10914-10930.	1.4	4
13	Identification of oleoylethanolamide as an endogenous ligand for HIF-3Î±. Nature Communications, 2022, 13, 2529.	5.8	19
14	A potent PGK1 antagonist reveals PGK1 regulates the production of IL-1Î² and IL-6. Acta Pharmaceutica Sinica B, 2022, 12, 4180-4192.	5.7	9
15	Discovery of <scp>CECR2</scp> Bromodomain Inhibitors with High Selectivities over <scp>BPTF</scp> Bromodomain. Chinese Journal of Chemistry, 2022, 40, 2072-2080.	2.6	0
16	Design, synthesis, and biological evaluation of novel carbazole derivatives as potent DNMT1 inhibitors with reasonable PK properties. Journal of Enzyme Inhibition and Medicinal Chemistry, 2022, 37, 1537-1555.	2.5	2
17	Leveraging Protein Dynamics to Identify Functional Phosphorylation Sites using Deep Learning Models. Journal of Chemical Information and Modeling, 2022, 62, 3331-3345.	2.5	7
18	A Peptide Binder of E3 Ligase Adaptor SPOP Disrupts Oncogenic SPOPâ€Protein Interactions in Kidney Cancer Cells. Chinese Journal of Chemistry, 2021, 39, 274-280.	2.6	3

#	Article	IF	Citations
19	Drug design targeting active posttranslational modification protein isoforms. Medicinal Research Reviews, 2021, 41, 1701-1750.	5.0	33
20	The methyltransferase PRMT1 regulates Î³-globin translation. Journal of Biological Chemistry, 2021, 296, 100417.	1.6	5
21	Gossypol, a novel modulator of VCP, induces autophagic degradation of mutant huntingtin by promoting the formation of VCP/p97-LC3-mHTT complex. Acta Pharmacologica Sinica, 2021, 42, 1556-1566.	2.8	8
22	PRMT1 is a novel molecular therapeutic target for clear cell renal cell carcinoma. Theranostics, 2021, 11, 5387-5403.	4.6	36
23	Discovery of a novel 53BP1 inhibitor through AlphaScreen-based high-throughput screening. Bioorganic and Medicinal Chemistry, 2021, 34, 116054.	1.4	7
24	Design, synthesis, and biological evaluation of 4-benzoylamino-1H-pyrazole-3-carboxamide derivatives as potent CDK2 inhibitors. European Journal of Medicinal Chemistry, 2021, 215, 113281.	2.6	12
25	Discovery and characterization of a novel glucose-6-phosphate dehydrogenase (G6PD) inhibitor via high-throughput screening. Bioorganic and Medicinal Chemistry Letters, 2021, 40, 127905.	1.0	5
26	Discovery of a subtype-selective, covalent inhibitor against palmitoylation pocket of TEAD3. Acta Pharmaceutica Sinica B, 2021, 11, 3206-3219.	5.7	21
27	Design, Synthesis, and Biological Evaluation of Novel Pyrimido[4,5-b]indole Derivatives Against Gram-Negative Multidrug-Resistant Pathogens. Journal of Medicinal Chemistry, 2021, 64, 8644-8665.	2.9	10
28	Structure-Guided Development of Small-Molecule PRC2 Inhibitors Targeting EZH2â€“EED Interaction. Journal of Medicinal Chemistry, 2021, 64, 8194-8207.	2.9	25
29	Structural basis of ketamine action on human NMDA receptors. Nature, 2021, 596, 301-305.	13.7	76
30	Discovery of High-Affinity Inhibitors of the BPTF Bromodomain. Journal of Medicinal Chemistry, 2021, 64, 12075-12088.	2.9	15
31	Inhibition of Autophagy by a Small Molecule through Covalent Modification of the LC3 Protein. Angewandte Chemie - International Edition, 2021, 60, 26105-26114.	7.2	36
32	Targeting p300/CBP Attenuates Hepatocellular Carcinoma Progression through Epigenetic Regulation of Metabolism. Cancer Research, 2021, 81, 860-872.	0.4	64
33	Ordered assembly of the cytosolic RNA-sensing MDA5-MAVS signaling complex via binding to unanchored K63-linked poly-ubiquitin chains. Immunity, 2021, 54, 2218-2230.e5.	6.6	23
34	Dynamics of Post-Translational Modification Inspires Drug Design in the Kinase Family. Journal of Medicinal Chemistry, 2021, 64, 15111-15125.	2.9	13
35	Design, synthesis and biological evaluation of a novel spiro oxazolidinedione as potent p300/CBP HAT inhibitor for the treatment of ovarian cancer. Bioorganic and Medicinal Chemistry, 2021, 52, 116512.	1.4	9
36	Metabolic Syndrome and Its Components Are Associated With Altered Amino Acid Profile in Chinese Han Population. Frontiers in Endocrinology, 2021, 12, 795044.	1.5	7

#	Article	IF	Citations
37	Discovery of Highly Potent, Selective, and Orally Efficacious p300/CBP Histone Acetyltransferases Inhibitors. Journal of Medicinal Chemistry, 2020, 63, 1337-1360.	2.9	85
38	Licochalcone A suppresses the proliferation of sarcoma HT-1080 cells, as a selective R132C mutant IDH1 inhibitor. Bioorganic and Medicinal Chemistry Letters, 2020, 30, 126825.	1.0	13
39	A patent review of BRD4 inhibitors (2013-2019). Expert Opinion on Therapeutic Patents, 2020, 30, 57-81.	2.4	42
40	Epigenetics 2.0: Special Issue on Epigeneticsâ€"Call for Papers. Journal of Medicinal Chemistry, 2020, 63, 12129-12130.	2.9	1
41	Structure-based drug optimization and biological evaluation of tetrahydroquinolin derivatives as selective and potent CBP bromodomain inhibitors. Bioorganic and Medicinal Chemistry Letters, 2020, 30, 127480.	1.0	6
42	Synthesis and structureâ€"activity relationship studies of LLY-507 analogues as SMYD2 inhibitors. Bioorganic and Medicinal Chemistry Letters, 2020, 30, 127598.	1.0	5
43	Radix Rehmanniae Praeparata promotes bone fracture healing through activation of TGF-Î² signaling in mesenchymal progenitors. Biomedicine and Pharmacotherapy, 2020, 130, 110581.	2.5	10
44	Rho Family Proteins: Covalent Inhibitors Allosterically Block the Activation of Rho Family Proteins and Suppress Cancer Cell Invasion (Adv. Sci. 14/2020). Advanced Science, 2020, 7, 2070079.	5.6	1
45	Covalent Inhibitors Allosterically Block the Activation of Rho Family Proteins and Suppress Cancer Cell Invasion. Advanced Science, 2020, 7, 2000098.	5.6	16
46	Design, synthesis, and biological evaluation of tetrahydroquinolin derivatives as potent inhibitors of CBP bromodomain. Bioorganic Chemistry, 2020, 101, 103991.	2.0	7
47	BRD4 inhibitor nitroxoline enhances the sensitivity of multiple myeloma cells to bortezomib in vitro and in vivo by promoting mitochondrial pathway-mediated cell apoptosis. Therapeutic Advances in Hematology, 2020, 11, 204062072093268.	1.1	10
48	Discovery of 8-Methyl-pyrrolo[1,2-a]pyrazin-1(2H)-one Derivatives as Highly Potent and Selective Bromodomain and Extra-Terminal (BET) Bromodomain Inhibitors. Journal of Medicinal Chemistry, 2020, 63, 3956-3975.	2.9	24
49	Discovery of a Potent and Selective NF-ÎºB-Inducing Kinase (NIK) Inhibitor That Has Anti-inflammatory Effects in Vitro and in Vivo. Journal of Medicinal Chemistry, 2020, 63, 4388-4407.	2.9	31
50	Lead discovery, chemical optimization, and biological evaluation studies of novel histone methyltransferase SET7 small-molecule inhibitors. Bioorganic and Medicinal Chemistry Letters, 2020, 30, 127061.	1.0	11
51	BRD4 as a therapeutic target for nonfunctioning and growth hormone pituitary adenoma. Neuro-Oncology, 2020, 22, 1114-1125.	0.6	19
52	Structureâ€"Activity Relationship of SPOP Inhibitors against Kidney Cancer. Journal of Medicinal Chemistry, 2020, 63, 4849-4866.	2.9	16
53	Rational Design, synthesis and biological evaluation of novel triazole derivatives as potent and selective PRMT5 inhibitors with antitumor activity. Journal of Computer-Aided Molecular Design, 2019, 33, 775-785.	1.3	14
54	Development and Characterization of a Fluorescent Probe for GLS1 and the Application for High-Throughput Screening of Allosteric Inhibitors. Journal of Medicinal Chemistry, 2019, 62, 9642-9657.	2.9	19

#	Article	IF	Citations
55	Discovery and biological evaluation of vinylsulfonamide derivatives as highly potent, covalent TEAD autopalmitoylation inhibitors. European Journal of Medicinal Chemistry, 2019, 184, 111767.	2.6	55
56	Discovery, structural insight, and bioactivities of BY27 as a selective inhibitor of the second bromodomains of BET proteins. European Journal of Medicinal Chemistry, 2019, 182, 111633.	2.6	36
57	Targeting epigenetic machinery: Emerging novel allosteric inhibitors. , 2019, 204, 107406.		32
58	Discovery of alkoxy benzamide derivatives as novel BPTF bromodomain inhibitors via structure-based virtual screening. Bioorganic Chemistry, 2019, 86, 494-500.	2.0	14
59	Design, Synthesis, and Biological Evaluation of Novel DNA Gyrase-Inhibiting Spiropyrimidinetriones as Potent Antibiotics for Treatment of Infections Caused by Multidrug-Resistant Gram-Positive Bacteria. Journal of Medicinal Chemistry, 2019, 62, 2950-2973.	2.9	24
60	Thymine DNA glycosylase recognizes the geometry alteration of minor grooves induced by 5-formylcytosine and 5-carboxylcytosine. Chemical Science, 2019, 10, 7407-7417.	3.7	20
61	Targeting PRMT5 Activity Inhibits the Malignancy of Hepatocellular Carcinoma by Promoting the Transcription of HNF4Î±. Theranostics, 2019, 9, 2606-2617.	4.6	40
62	Discovery of betulinaldehyde as a natural RORÎ³t agonist. FÃ¬toterapÃ¬Ã¢, 2019, 137, 104200.	1.1	7
63	1-Phenyl-dihydrobenzoindazoles as novel colchicine site inhibitors: Structural basis and antitumor efficacy. European Journal of Medicinal Chemistry, 2019, 177, 448-456.	2.6	12
64	Reduced asymmetric dimethylarginine accumulation through inhibition of the type I protein arginine methyltransferases promotes renal fibrosis in obstructed kidneys. FASEB Journal, 2019, 33, 6948-6956.	0.2	18
65	Discovery of trisubstituted nicotinonitrile derivatives as novel human GCN5 inhibitors through AlphaScreen-based high throughput screening. RSC Advances, 2019, 9, 4917-4924.	1.7	8
66	Discovery of 2-substituted-N-(3-(3,4-dihydroisoquinolin-2(1H)-yl)-2-hydroxypropyl)-1,2,3,4-tetrahydroisoquinoline-6-carboxamide as potent and selective protein arginine methyltransferases 5 inhibitors: Design, synthesis and biological evaluation. European Journal of Medicinal Chemistry, 2019, 164, 317-333.	2.6	19
67	The identification of novel small-molecule inhibitors targeting WDR5-MLL1 interaction through fluorescence polarization based high-throughput screening. Bioorganic and Medicinal Chemistry Letters, 2019, 29, 638-645.	1.0	11
68	Rational design of 5-((1H-imidazol-1-yl)methyl)quinolin-8-ol derivatives as novel bromodomain-containing protein 4 inhibitors. European Journal of Medicinal Chemistry, 2019, 163, 281-294.	2.6	13
69	Machine Learning Methods in Precision Medicine Targeting Epigenetic Diseases. Current Pharmaceutical Design, 2019, 24, 3998-4006.	0.9	7
70	A patent review of arginine methyltransferase inhibitors (2010â€“2018). Expert Opinion on Therapeutic Patents, 2019, 29, 97-114.	2.4	78
71	One-step fabrication of robust superhydrophobic and superoleophilic surfaces with self-cleaning and oil/water separation function. Scientific Reports, 2018, 8, 3869.	1.6	102
72	Identification of Selective, Cell Active Inhibitors of Protein Arginine Methyltransferase 5 through Structure-Based Virtual Screening and Biological Assays. Journal of Chemical Information and Modeling, 2018, 58, 1066-1073.	2.5	12

#	Article	IF	Citations
73	Identification of a novel selective small-molecule inhibitor of protein arginine methyltransferase 5 (PRMT5) by virtual screening, resynthesis and biological evaluations. Bioorganic and Medicinal Chemistry Letters, 2018, 28, 1476-1483.	1.0	18
74	Discovery of 1,8-acridinedione derivatives as novel GCN5 inhibitors via high throughput screening. European Journal of Medicinal Chemistry, 2018, 151, 740-751.	2.6	29
75	Metabolite identification of ursolic acid in mouse plasma and urine after oral administration by ultra-high performance liquid chromatography/quadrupole time-of-flight mass spectrometry. RSC Advances, 2018, 8, 6532-6539.	1.7	17
76	Biochemical Studies and Molecular Dynamic Simulations Reveal the Molecular Basis of Conformational Changes in DNA Methyltransferase-1. ACS Chemical Biology, 2018, 13, 772-781.	1.6	24
77	Design, synthesis and biological evaluation of benzo[cd]indol-2(1H)-ones derivatives as BRD4 inhibitors. European Journal of Medicinal Chemistry, 2018, 152, 264-273.	2.6	20
78	Bioinspired surface functionalization of metallic biomaterials. Journal of the Mechanical Behavior of Biomedical Materials, 2018, 77, 90-105.	1.5	146
79	Interaction assessments of the first S-adenosylmethionine competitive inhibitor and the essential interacting partner methylosome protein 50 with protein arginine methyltransferase 5 by combined computational methods. Biochemical and Biophysical Research Communications, 2018, 495, 721-727.	1.0	13
80	Development and evaluation of a novel series of Nitroxoline-derived BET inhibitors with antitumor activity in renal cell carcinoma. Oncogenesis, 2018, 7, 83.	2.1	10
81	Structural Basis of the Proton Sensitivity of Human GluN1-GluN2A NMDA Receptors. Cell Reports, 2018, 25, 3582-3590.e4.	2.9	47
82	Identification of small molecule inhibitors targeting the SMARCA2 bromodomain from a high-throughput screening assay. Acta Pharmacologica Sinica, 2018, 39, 1544-1552.	2.8	18
83	Small Molecule Inhibitors Targeting New Targets of Protein-Protein Interactions. , 2018, , 179-211.		1
84	Discovery and biological evaluation of thiobarbituric derivatives as potent p300/CBP inhibitors. Bioorganic and Medicinal Chemistry, 2018, 26, 5397-5407.	1.4	19
85	Current Strategies and Applications for Precision Drug Design. Frontiers in Pharmacology, 2018, 9, 787.	1.6	32
86	Design, synthesis and anti leukemia cells proliferation activities of pyrimidylaminoquinoline derivatives as DOT1L inhibitors. Bioorganic Chemistry, 2018, 80, 649-654.	2.0	11
87	Computer-Aided Drug Design in Epigenetics. Frontiers in Chemistry, 2018, 6, 57.	1.8	51
88	Identification of novel inhibitors of histone acetyltransferase hMOF through high throughput screening. European Journal of Medicinal Chemistry, 2018, 157, 867-876.	2.6	11
89	Identification of recurrent USP48 and BRAF mutations in Cushingâ€™s disease. Nature Communications, 2018, 9, 3171.	5.8	106
90	Identification of 5-benzylidene-2-phenylthiazolones as potent PRMT5 inhibitors by virtual screening, structural optimization and biological evaluations. Bioorganic Chemistry, 2018, 81, 289-298.	2.0	19

#	Article	IF	Citations
91	Development of a high-throughput fluorescence polarization assay for the discovery of EZH2-EED interaction inhibitors. Acta Pharmacologica Sinica, 2018, 39, 302-310.	2.8	19
92	Discovery of novel BRD4 inhibitors by high-throughput screening, crystallography, and cell-based assays. Bioorganic and Medicinal Chemistry Letters, 2017, 27, 2003-2009.	1.0	9
93	Discovery of Novel Disruptor of Silencing Telomeric 1-Like (DOT1L) Inhibitors using a Target-Specific Scoring Function for the (S)-Adenosyl-<scp>l</scp>-methionine (SAM)-Dependent Methyltransferase Family. Journal of Medicinal Chemistry, 2017, 60, 2026-2036.	2.9	22
94	Discovery of alkyl bis(oxy)dibenzimidamide derivatives as novel protein arginine methyltransferase 1 (<scp>PRMT</scp>1) inhibitors. Chemical Biology and Drug Design, 2017, 90, 1260-1270.	1.5	15
95	Machine-Learning-Assisted Approach for Discovering Novel Inhibitors Targeting Bromodomain-Containing Protein 4. Journal of Chemical Information and Modeling, 2017, 57, 1677-1690.	2.5	40
96	Discovery and optimization of selective inhibitors of protein arginine methyltransferase 5 by docking-based virtual screening. Organic and Biomolecular Chemistry, 2017, 15, 3648-3661.	1.5	28
97	Discovery of novel trimethoxy-ring BRD4 bromodomain inhibitors: AlphaScreen assay, crystallography and cell-based assay. MedChemComm, 2017, 8, 1322-1331.	3.5	13
98	Development of Potent Type I Protein Arginine Methyltransferase (PRMT) Inhibitors of Leukemia Cell Proliferation. Journal of Medicinal Chemistry, 2017, 60, 8888-8905.	2.9	39
99	NatD promotes lung cancer progression by preventing histone H4 serine phosphorylation to activate Slug expression. Nature Communications, 2017, 8, 928.	5.8	69
100	Discovery of novel BET inhibitors by drug repurposing of nitroxoline and its analogues. Organic and Biomolecular Chemistry, 2017, 15, 9352-9361.	1.5	34
101	Conformation and dynamics of the C-terminal region in human phosphoglycerate mutase 1. Acta Pharmacologica Sinica, 2017, 38, 1673-1682.	2.8	9
102	Potent, Selective, and Cell Active Protein Arginine Methyltransferase 5 (PRMT5) Inhibitor Developed by Structure-Based Virtual Screening and Hit Optimization. Journal of Medicinal Chemistry, 2017, 60, 6289-6304.	2.9	53
103	Identification of Novel Inhibitors against Coactivator Associated Arginine Methyltransferase 1 Based on Virtual Screening and Biological Assays. BioMed Research International, 2016, 2016, 1-8.	0.9	7
104	Discovery of Substituted 1H-Pyrazolo[3,4-b]pyridine Derivatives as Potent and Selective FGFR Kinase Inhibitors. ACS Medicinal Chemistry Letters, 2016, 7, 629-634.	1.3	58
105	Small-Molecule Targeting of E3 Ligase Adaptor SPOP in Kidney Cancer. Cancer Cell, 2016, 30, 474-484.	7.7	74
106	Discovery of Novel Inhibitors Targeting the Menin-Mixed Lineage Leukemia Interface Using Pharmacophore- and Docking-Based Virtual Screening. Journal of Chemical Information and Modeling, 2016, 56, 1847-1855.	2.5	22
107	Identification of novel small-molecule inhibitors targeting meninâ€“MLL interaction, repurposing the antidiarrheal loperamide. Organic and Biomolecular Chemistry, 2016, 14, 8503-8519.	1.5	17
108	Potent Antitumor Activities and Structure Basis of the Chiral Î²-Lactam Bridged Analogue of Combretastatin A-4 Binding to Tubulin. Journal of Medicinal Chemistry, 2016, 59, 10329-10334.	2.9	75

#	Article	IF	Citations
109	Discovery of 3-(5â€²-Substituted)-Benzimidazole-5-(1-(3,5-dichloropyridin-4-yl)ethoxy)-1H-indazoles as Potent Fibroblast Growth Factor Receptor Inhibitors: Design, Synthesis, and Biological Evaluation. Journal of Medicinal Chemistry, 2016, 59, 6690-6708.	2.9	44
110	Identification of Novel Disruptor of Telomeric Silencing 1-like (DOT1L) Inhibitors through Structure-Based Virtual Screening and Biological Assays. Journal of Chemical Information and Modeling, 2016, 56, 527-534.	2.5	27
111	Meclofenamic acid selectively inhibits FTO demethylation of m6A over ALKBH5. Nucleic Acids Research, 2015, 43, 373-384.	6.5	453
112	Quantum Chemistry Calculation-Aided Structural Optimization of Combretastatin A-4-like Tubulin Polymerization Inhibitors: Improved Stability and Biological Activity. Journal of Medicinal Chemistry, 2015, 58, 2538-2546.	2.9	15
113	In vitro inhibitory activities of six gypenosides on human liver cancer cell line HepG2 and possible role of HIF-1Î± pathway in them. Chemico-Biological Interactions, 2015, 238, 48-54.	1.7	19
114	Discovery and Optimization of Novel, Selective Histone Methyltransferase SET7 Inhibitors by Pharmacophore- and Docking-Based Virtual Screening. Journal of Medicinal Chemistry, 2015, 58, 8166-8181.	2.9	59
115	Structural insight into substrate preference for TET-mediated oxidation. Nature, 2015, 527, 118-122.	13.7	213
116	Inhibition of human copper trafficking by a small molecule significantly attenuates cancer cell proliferation. Nature Chemistry, 2015, 7, 968-979.	6.6	205
117	Influences of gold and silver nanoparticles in loop-mediated isothermal amplification reactions. Journal of Experimental Nanoscience, 2014, 9, 922-930.	1.3	8
118	Metadynamics Simulation Study on the Conformational Transformation of HhaI Methyltransferase: An Induced-Fit Base-Flipping Hypothesis. BioMed Research International, 2014, 2014, 1-13.	0.9	14
119	Virtual screening and biological evaluation of novel small molecular inhibitors against protein arginine methyltransferase 1 (PRMT1). Organic and Biomolecular Chemistry, 2014, 12, 9665-9673.	1.5	27
120	Astemizole Arrests the Proliferation of Cancer Cells by Disrupting the EZH2-EED Interaction of Polycomb Repressive Complex 2. Journal of Medicinal Chemistry, 2014, 57, 9512-9521.	2.9	96
121	Identifying Novel Selective Non-Nucleoside DNA Methyltransferase 1 Inhibitors through Docking-Based Virtual Screening. Journal of Medicinal Chemistry, 2014, 57, 9028-9041.	2.9	96
122	Antiinfective therapy with a small molecule inhibitor of Staphylococcus aureus sortase. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, 13517-13522.	3.3	128
123	Inhibition of HepG2 cell proliferation by ursolic acid and polysaccharides via the downregulation of cyclooxygenase-2. Molecular Medicine Reports, 2014, 9, 2505-2511.	1.1	26
124	Computational methods for drug design and discovery: focus on China. Trends in Pharmacological Sciences, 2013, 34, 549-559.	4.0	70
125	Theoretical Insights into Catalytic Mechanism of Protein Arginine Methyltransferase 1. PLoS ONE, 2013, 8, e72424.	1.1	17
126	Thymine DNA glycosylase specifically recognizes 5-carboxylcytosine-modified DNA. Nature Chemical Biology, 2012, 8, 328-330.	3.9	273

#	Article	IF	Citations
127	Development of a novel class of B-RafV600E-selective inhibitors through virtual screening and hierarchical hit optimization. Organic and Biomolecular Chemistry, 2012, 10, 7402.	1.5	20
128	Comparison of Inhibitory Effects of Nine Flavonoids on Prostaglandin E2 Production and COX-2 Expression in LPS-Stimulated RAW264.7 Macrophages. , 2012, , .		2
129	Development of Cell-Active N⁶-Methyladenosine RNA Demethylase FTO Inhibitor. Journal of the American Chemical Society, 2012, 134, 17963-17971.	6.6	314
130	MicroRNA expression analysis reveals significant biological pathways in human prostate cancer. , 2011, , .		1
131	Inhibition of autophagy by a small molecule through covalent modification of LC3. Angewandte Chemie, 0, , .	1.6	0